Cancer development is influenced by hereditary mutations, somatic mutations due to random errors in DNA replication, or external factors. It remains unclear how distinct cellintrinsic and -extrinsic factors impact oncogenesis within the same tissue type. We investigated murine soft tissue sarcomas generated by oncogenic alterations (Kras G12D activation and p53 deletion), carcinogens (3-methylcholanthrene [MCA] or ionizing radiation), and in a novel model combining both factors (MCA plus p53 deletion). Wholeexome sequencing demonstrated distinct mutational signatures in individual sarcoma cohorts. MCA-induced sarcomas exhibited high mutational burden and predominantly G-to-T transversions, while radiation-induced sarcomas exhibited low mutational burden and a distinct genetic signature characterized by C-to-T transitions. The indel to substitution ratio and amount of gene copy number variations were high for radiation-induced sarcomas. MCA-induced tumors generated on a p53-deficient background showed the highest genomic instability. MCA-induced sarcomas harbored mutations in putative cancer-driver genes that regulate MAPK signaling (Kras and Nf1) and the Hippo pathway (Fat1 and Fat4).
INTRODUCTION
Approximately 50% of all cancer patients receive radiation therapy (1) ,which is a component of approximately 40% of all cancer cures (2) . While radiation is an effective cancer therapy, its use involves a small, but clinically significant risk of developing a therapy-related malignancy(3).
Radiation-associated cancers develop years later and are a particular concern for pediatric cancer patients as they may carry germline mutations in oncogenes or tumor suppressors genes and as they have many years to develop secondary cancers. Moreover, the estimated total lifetime risk of radiation-associated cancers may be higher in patients receiving modern radiation therapy techniques, such as intensity modulated radiation therapy (IMRT) and image guided radiation therapy (IGRT) (4, 5) . When a second cancer develops after radiation exposure, it can be challenging to determine whether radiation caused the tumor.
Radiotherapy kills cells by generating unresolved double stranded DNA breaks. For example, cells undergo mitosis with unrepaired double stranded DNA breaks after radiotherapy can die through mechanisms including mitotic catastrophe (6) . While radiation effectively kills proliferating cancer cells, it is a relatively weak carcinogen (3, 7) . In contrast, the potent chemical carcinogen 3-methylcholanthrene (MCA) is non-lethal, but acts as a mutagen to modify DNA sequences, primarily causing G to T transversions (8) . Mutagenesis initiates a selection process that favors proliferative cells harboring activated oncogenes and inactivated tumor suppressor genes. However, mechanisms by which radiation-induced DNA damage and repair processes cause de novo cancer formation, as well as the specific types of DNA mutations and pathways modulated, remain poorly understood.
To identify mutational signatures specific to radiation-induced tumors and to gain insight into how distinct cell-intrinsic and -extrinsic factors impact cancer development within the same tissue type, we performed genomic analysis across murine soft-tissue sarcomas induced by MCA, oncogenic mutations, or ionizing radiation. Radiation-induced sarcomas were generated by focally irradiating the mouse hind limb using a single dose of [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . For comparison to radiation-induced sarcomas, we utilized an established genetically engineered mouse model of soft tissue sarcoma in which localized delivery of Cre recombinase into the muscle of the hind limb activates oncogenic Kras G12D and deletes both alleles of p53 (10) . In addition, we generated MCA-induced sarcomas in the hind limb of either WT or p53 FL/FL mice in which both copies of p53 were deleted by Cre recombinase.
Using these mouse models of oncogene-driven, chemical carcinogen-induced or radiation-induced soft tissue sarcoma, we performed whole-exome sequencing (WES) on paired tumor and normal tissue from each mouse and observed distinct facultative molecular signatures that are specific to each carcinogenic driver. Remarkably, ionizing radiation produced tumors with relatively low levels of nonsynonymous mutations, but a high frequency of somatic copynumber alterations, with a preponderance of deletions and a predilection for C to T and G to A transitions.
RESULTS

Generation of primary murine sarcomas by oncogenic alterations, chemical carcinogens, and ionizing radiation
To investigate how cell-intrinsic and -extrinsic factors impact cancer development within the same tissue type, we generated primary murine sarcomas by using defined genetic and external insults including mutations of Kras and p53(10) (Kras G12D p53 -/-), chemical carcinogen MCA (11) (MCA-induced p53 WT and MCA-induced p53 -/-) and ionizing radiation(9) (IR-induced) ( Figure 1a and Table S1 ). Kras G12D p53 -/-sarcomas were generated in LSL-Kras G12D ; p53 FL/FL mice following intramuscular delivery of adenovirus expressing Cre recombinase (Ad-Cre) (10) .
The median of the observed event times for the six mice with Kras G12D p53 -/-sarcomas for which data were available was 77 days after Ad-Cre injection. The latency of Kras G12D p53 -/-sarcomas was similar to MCA-induced p53 -/-sarcomas, which were generated via intramuscular injection of both Ad-Cre and MCA into p53 FL/FL mice ( Table S2 ). Compared to MCA-induced p53 -/-and Kras G12D p53 -/-sarcomas, MCA-induced sarcomas generated in p53 WT mice had markedly longer latency (Table S2) . Notably, IR-induced sarcomas, which developed in mice with or without temporary (10 day) p53 knockdown during a single dose of 30 or 40 Gy focal irradiation (12) , had the longest observed latency. The median observed event time was 449 days after radiation exposure (Table S2) . Histology demonstrated that sarcomas generated by these approaches were intermediate-to high-grade soft tissue sarcomas ( Figure S1 ). Collectively, these mouse models provide a unique resource to comprehensively understand the mutational landscape across soft tissue sarcomas generated through distinct oncogenic alterations and carcinogens.
Tumor-initiating factors dictate mutational load and signatures
To determine the mutational landscape of soft tissue sarcomas, we performed WES on paired tumor and normal liver to identify somatic mutations that are specific to each tumor model IR-induced sarcomas harbored a substantially lower mutational load with a median of 26 nonsynonymous mutations per tumor. The mutational burden of IR-induced sarcomas was similar to Kras G12D p53 -/-sarcomas ( Figure 1, b and c) . Notably, a single IR-induced sarcoma (S28) exhibited a disproportionally high number of mutations, of which about 15% were localized on chromosome 2 ( Figure S3 ). Further examination of S28 revealed mutations in multiple genes that control the DNA damage response, including Brca1, Atrx, and Pole ( Table   S3 ), suggesting that defects in DNA repair and cell cycle checkpoint controls lead to an accumulation of mutations in this tumor (13) . Together, these results indicate that while MCA generates sarcomas by causing gene mutations, ionizing radiation does not typically induce sarcomas by increasing mutational burden.
In addition to assessing the number of mutations, we examined the impact of different genetic and external insults on the distribution of sequence variants, including single-nucleotide variants (SNVs) and insertions-deletions (indels) (Figure 1d and Figure S4 ). We further conducted signature analysis using nonnegative matrix factorization (NMF) (14) , and compared our results to 30 published signatures identified in human cancers 
Ionizing radiation and p53 status contribute to increased copy number variations
In addition to examining mutations, we evaluated somatic copy number variations (CNVs) using 
Different sarcoma cohorts show enrichment in genes affected by mutations versus CNVs
To elucidate genetic alterations that contribute to sarcoma development, we compared the To examine genetic alterations that potentially contribute to oncogenesis, we evaluated specific oncogenic genes that were impacted by mutations and CNVs using the COSMIC database. While the number of nonsynonymous mutations in COSMIC genes was extremely low in radiation-induced and Kras G12D p53 -/-sarcomas, frequent mutations were observed in COSMIC genes in the MCA-induced tumors (Figure 3c ). In contrast, the median number of COSMIC genes affected by CNVs was higher in IR-induced sarcomas, Kras G12D p53 -/-sarcomas and MCA-induced p53 -/-sarcomas compared to MCA-induced p53 WT sarcomas (Figure 3d ).
Mutations in putative driver genes of sarcomas
To evaluate putative driver genes, we analyzed recurring nonsynonymous mutations and CNVs of COSMIC genes in different sarcoma cohorts. Kras G12D p53 -/-sarcomas showed essentially no recurring mutations in COSMIC genes. IR-induced sarcomas harbored recurring mutations in only four COSMIC genes, despite the analysis including the hypermutated sample S28 ( Figure   4a ). In contrast, MCA-induced sarcomas exhibited a high frequency of mutations in numerous putative driver genes, including Kras and NF1 (Figure 4b ). Of note, we observed p53 mutations in 100% of sarcomas (6 out 
DISCUSSION
Radiation-associated sarcomas are a rare but significant potential late side effect of radiation therapy (17) . However, methods are currently lacking to discern whether a second malignancy is caused by radiation exposure. To date, a robust mutational signature for distinguishing ionizing radiation-initiated cancers from tumors driven by other pathogenetic events has not been defined.
Because the genetic drivers of radiation-related cancers may differ from spontaneous cancers, identifying specific genetic features in tumors that contribute to an ionizing radiation signature has the potential to not only to impact diagnosis, but also therapy. Searching for a genetic signature of radiation-associated cancer in human samples is complicated by variations in radiation dose and fractionation, anatomic location, tumor type, and uncertainty regarding whether radiation initiated the tumor. By contrast, our primary murine sarcoma models provide a well-controlled system to search for a genetic signature of radiation-driven tumorigenesis. We A mutational signature depends on the mechanism of mutagenesis and subsequent selection process that malignant cells undergo during tumor development. For example, MCA metabolites form covalent bonds with double-and single-stranded DNA, preferentially at guanine residues to produce G to T transversions (8) . Therefore, the specific base changes that predominate in the MCA-induced p53 WT and MCA-induced p53 -/-sarcomas are G to T and the reverse (C to A) single base substitutions (Figure 1f) . Ionizing radiation generates DNA damage when energy is directly absorbed by DNA molecules and indirectly through ionization of water or other intracellular molecules to generate hydroxyl radicals that cause 2-deoxyribose oxidation (18, 19) . Guanine residues are particularly sensitive to oxidation compared to cytosine, thymine, and adenine, and 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxoG) is among the most readily detected base products after ionizing radiation (20) . Subsequently, 8-oxoG itself is far more susceptible to further oxidation, yielding more stable molecules including spiroiminodihydantion and guanidinohydantoin which are more mutagenic(18). 8-oxoG adducts predominately lead to G:C to T:A transitions (21) . Furthermore, reactive oxygen species through
Fenton chemistry lead to deamination of methylated cytosines and thymine single base substitutions (22, 23) . Therefore, G to A and C to T DNA transition mutations are hallmarks of oxidative damage (23) . Previous analysis of radiation-associated human tumors (24, 25) and radiation-induced mouse tumors(26) reported a prevalence of C to T transitions. Our data, which include specific controls for alternative tumor initiating events, demonstrate a preference for C to T and the reverse (G to A) base sequence mutations in radiation-induced tumors (Figure 1f) , indicating a strong oxidative mutation signature generated by ionizing radiation.
While the single base substitution patterns for each tumor model reveal distinguishing underlying mechanistic information, the overall somatic mutational load also provides insights into tumor initiation. MCA is a potent mutagen that generates sarcomas with roughly 80 times the median number of mutations compared to IR-induced sarcomas or Kras G12D p53 -/-sarcomas (Figure 1b) . Thus, the MCA-driven p53 -/-sarcomas represent a novel spatially-and temporallyrestricted high mutational load mouse model in which autochthonous tumors develop over 10-18 weeks (Table S2) , evolving under the selective pressure of an intact immune system. In contrast to conventional genetically engineered mouse models, such as the Kras G12D p53 -/-sarcomas, the MCA-driven p53 -/-sarcomas exhibit a mutational load similar to many human cancers that respond to immunotherapy (27, 28) . Therefore, this model will be an important new tool to study the co-evolution of tumors with the immune system and a pre-clinical platform to test immunotherapy.
Remarkably, the radiation-induced sarcomas exhibited relatively few nonsynonymous somatic mutations (Figure 1c) . The low mutational load in the radiation-induced tumors is surprising, but this is consistent with radiation acting as a relatively weak carcinogen(3, 7).
Notably, others have reported higher mutational loads in radiation-induced mouse tumors (26) .
Potential explanations for this discrepancy include differences in tumor types analyzed, radiation dose and fractionation. Moreover, a reference genome was used to call somatic mutations (26), which has the potential to increase the number of called mutations. In contrast, we performed WES using paired normal tissue as the reference for each tumor. Consistent with our findings, studies examining human radiation-associated tumors reported a relatively low mutational load (24, 25, 29) . Because we did not sequence other tumor types or include tumors that developed after fractionated radiation exposure, the signature defined herein may not be universal for all radiation-induced cancers.
Although radiation-induced sarcomas exhibited a low number of mutations, they were comprised of a higher proportion of nonsynonymous deletion events compared to Kras G12D p53
-/-and MCA-driven sarcomas (Figure 1e ). This result corroborates the finding from Behjati et al. (25) , showing that insertions and deletions were not equally represented in human radiationassociated second malignancies, but rather that deletions were enriched and evenly distributed throughout the genome (25) . Although deletions were relatively common, perhaps suggesting a loss of tumor suppressor function, none of the radiation-induced sarcomas in this study exhibited a mutation in the p53 gene. In fact, no specific driver mutations were identified in this tumor cohort (Figure 4a) . However, the low mutational burden observed by WES in the mouse radiation-induced sarcomas represents a limitation for identifying specific driver mutations and conducting NMF signature analysis. In contrast, gene copy number changes were more abundant in radiation-induced sarcomas compared to Kras G12D p53 -/-and MCA-driven tumors. Oncogenes
Met, Yap1 and Birc3 each exhibited copy number gains in approximately half of the radiationinduced tumors (Figure 5c) . Notably, the Yap1 pathway is commonly activated in rhabdomyosarcomas and Yap1 overexpression in muscle satellite cells is sufficient to induce sarcomagenesis in the context of muscle injury (30) .
In contrast to the radiation-induced tumors which retained wild type p53 genes, all MCAinduced tumors from wild type mice acquired a p53 mutation (Figure 4b and Figure S7 ). (Figure 4b ). These findings suggest that p53 mutation timing, prior to versus as a consequence of MCA exposure, shapes the mutational landscape by altering the selective pressure for cells to mutate specific genes.
Notably, Kras was mutated in half of all MCA-driven tumors independent of p53 status.
Moreover, the tumor suppressor Fat1 was mutated in nearly all MCA tumors, and Fat4, Notch2
and NF1 were also commonly disrupted (Figure 4b) . Our study comports with sequencing data from a commonly used MCA-driven sarcoma cell line derived from immunodeficient mice (Rag2 -/-)(31). Furthermore, our comprehensive analysis of a large cohort of MCA-driven tumors supports the utility of this well characterized primary mouse model of sarcoma for preclinical drug development studies in the presence of an intact immune system.
The genetic landscape of radiation-induced tumors reported here is distinct form published signatures for other carcinogenic processes, such as aging (32) or UV exposure (33) . In studies examining radiation-associated liver tumors, higher radiation dose resulted in an increased fraction of cells harboring p53 mutations, likely through a clonal expansion mechanism (34) . We previously published a report detailing the non-cell-autonomous mechanism by which radiation induces lymphomagenesis (12) . In this case, total-body irradiation eliminates cells in the bone marrow niche, allowing thymic cells with preexisting oncogenic mutations to expand into a tumor unencumbered by cell competition from the bone marrow. However, the mechanisms for radiation-induced sarcomagenesis may be distinct from radiation-induced lymphomagenesis. The WES provides evidence of radiation-induced oxidative DNA damage and amplification of genes such as Met and Yap1, which are both associated with injury-induced sarcomas (35) , suggesting a cell-autonomous mechanism. We suspect that after tumor-initiating cells undergo radiation-induced DNA damage, they begin clonal expansion and develop into a tumor through a selection process shaped by acute and chronically injured surrounding tissue following radiation exposure. The microenvironment of irradiated tissue is characterized by high levels of inflammatory cells and increased growth factor secretion to stimulate wound healing.
Tumors that arise under these conditions are adapted to take advantage of the abundant cytokines in this milieu (36) . Therefore, radiation-induced cancer may respond to different therapeutic approaches, including immunotherapy, compared to tumors from the same tissue that develop independent of radiation exposure. Defining a signature of radiation-induced cancer that can identify and characterize these tumors is a critical step toward optimizing treatment for this challenging clinical problem.
MATERIALS AND METHODS
Mouse strains and sarcoma induction
To study IR-induced sarcomas, we used previously described mouse models expressing a doxycycline-inducible shRNA against p53 including CMV-rtTA; TRE-p53.1224 and Actin-rtTA; TRE-p53.1224 mice as well as their littermates that only express rtTA or TRE-p53.1224 (12) . All mice were on a C3H and C57BL/6J mixed genetic background. Six to 24-week-old mice were placed on a doxycycline diet for ten days prior to irradiation (12) . The left hind limb of the mice was irradiated with 30 or 40 Gy, and then animals were immediately returned to normal chow.
Hind limb irradiation was performed using the X-RAD 225Cx small animal image-guided irradiator (Precision X-Ray). The irradiation field included the whole left hind limb and was defined using fluoroscopy with 40 kVp, 2.5 mA X-rays using a 2 mm Al filter. Irradiations were performed using parallel-opposed anterior and posterior fields with an average dose rate of 300 cGy/min prescribed to midplane with 225 kVp, 13 mA X-rays using a 0.3 mm Cu filter.
Genetically engineered and carcinogen-induced primary sarcomas were generated in 6 to 10-week-old mice with a mixed genetic background. Primary Kras G12D , p53 -/-sarcomas were ), 24 hours later followed by 300 µg injection of MCA.
After treatment, mice were examined weekly for sarcomas. Upon detection, tumors were harvested with half submerged in RNAlater (ThermoFisher Scientific) for subsequent DNA isolation and half formalin-fixed for histological analysis. Livers were collected for normal tissue control samples.
WES methods
Tumor specimens and matched liver control stored in RNAlater were used for DNA extraction.
DNA extraction was performed using DNeasy Blood and Tissue Kit or AllPrep DNA/RNA Mini Kit (Qiagen). WES was performed in two batches either using previously described methods (Batch 1)(35) or with the following method (Batch2) ( Table S1 ). One mouse in the Kras G12D p53 -/-cohort, S45, was excluded from analyses after whole-exome sequencing showed no evidence of a deletion of p53 exons two to ten. Genomic DNA samples were quantified using (Table S8 ). This pooling scheme generated about 14.5-63.5 million reads per sample or about 6Gb of data. Once generated, sequence data were demultiplexed and Fastq files were generated using Bcl2Fastq2 conversion software provided by Illumina. The sequencing data along with the called mutations in vcf format have been deposited onto NCBI Sequence Read Archive (SRA) under project ID: PRJNA516973.
WES data analyses
Somatic mutation calling: The raw sequences were first aligned to the mouse reference genome using the BWA-MEM algorithm (v0.7.12-r1039) (37) . The reference genome was obtained from Sanger Institute FTP site (ftp://ftp-mouse.sanger.ac.uk/). Reference germline information was obtained from the GATK bundle, somatic mutation information was from COSMIC (38) , and SNPs were annotated using SNPeff (39) and Oncotator (40) . The original capture file, which had been built on GRCm37 (mm9), was lifted to GRCm38 (mm10) to match with the other reference files. The aligned bam files were preprocessed by using picard-tools (v2.8.3;
http://broadinstitute.github.io/picard/faq.html), followed by somatic mutation detection using GATK3-MuTect2 (41) . The impact of called mutations was evaluated using Ensembl's Variant Effect Predictor (VEP) (v91.3) (42) and visualized using R package pheatmap (43) .
Somatic mutation plots:
Called mutations (SNVs and indels) in GATK3-MuTect2 and annotated by VEP as having "High" or "Moderate" impact were considered "protein-altering". To determine oncogenic drivers, the COSMIC database(44) was used as a consistent, communityaccepted database of tumor suppressors and oncogenes (Release v85). Tier 1 genes were downloaded from the Cancer Gene Census, fusion-only genes removed, and input into
MouseMine to determine murine homologues of these oncogenes and tumor suppressor genes.
The list of protein-altering mutations was filtered to only those mutations occurring within one of the identified genes, using the Bioconductor(45) R package biomaRt (46) Copy number variation: CNV was analyzed using CODEX2 (16) and visualized using R package pheatmap (v1.0.12)(43). Segments of estimated variation were compared to gene positions using the Bioconductor(45) annotation packages TxDb.Mmusculus.UCSC.mm10.knownGene(48) and org.Mm.eg.db (49) . If a gene was intersected by more than one segment, the estimated variation with the longest sequence overlap was retained. Genes with absolute estimated variations greater than 0.2 were considered CNVs. This threshold was determined based on the observed estimated variation of the p53 gene in samples from p53 deleted sarcoma cohorts ( Figure S8) . Genes with CNVs in three or more samples from one tumor cohort were included in the figures.
qRT-PCR
Relative genomic DNA levels were determined using qPCR assays performed on the 
Immunohistochemistry
Tumor tissue was fixed in 10% neutral buffered formalin for 24-48 hours, preserved in 70% ethanol, and embedded in paraffin. Tissues were sectioned onto a slide and stained with hematoxylin and eosin.
Statistical considerations
The p-values presented were two-sided, were the results of post-hoc analyses, and were not adjusted for multiple testing. When comparing a quantitative phenotype with respect to two groups, the Mann-Whitney U test was used, while for three or more groups, the Kruskal-Wallis test was used. All inferential analyses were carried out using the R statistical environment (50) along with extension packages from the comprehensive R archive network (CRAN;
https://cran.r-project.org/) and the Bioconductor project (45) . Box and whisker plots presented in the figures were constructed as follows: the center line indicated the median value, the bounds represented the first and third quartiles, and the whiskers extended to either a length of 1.5 times the inter-quartile range past the bounds, or the most extreme data value (i.e., minimum or maximum), whichever was shorter. In box and scatter plots, each dot represented the data for one tumor, unless otherwise indicated. In bar plots, each bar represented the data for one tumor, unless otherwise indicated.
Computational considerations
The analyses were conducted with adherence to the principles of reproducible analysis using the knitr package(51) for generation of dynamic reports and mercurial (https://www.mercurialscm.org/) for source code management. The code for replicating the statistical analysis was made available through a public source code repository (https://bitbucket.org/dcibioinformatics/kirschlee-sarcoma-wes/src/default/, commit ID 13:82732a597433).
Study approval
All animal procedures for this study were approved by the Institutional Animal Care and Use Committee (IACUC) at Duke University, Durham, NC, USA. The number of genes affected by CNVs. IR-induced sarcomas exhibited higher numbers of genes affected by CNVs than MCA-induced p53 WT sarcomas (p=0.0262). C, The number of genes with copy number gains. IR-induced sarcomas exhibited higher numbers of genes with copy number gains than MCA-induced p53 WT sarcomas (p=0.0262). D, The number of genes with copy number losses. IR-induced sarcomas exhibited higher numbers of genes with copy number losses than MCA-induced p53 WT sarcomas (p=0.297). P-values were calculated by the MannWhitney U test. Panels illustrate the data for n=37 tumors. 
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